Persistent IgG anticardiolipin autoantibodies are associated with post-COVID syndrome

Bertin, Daniel; Kaphan, Elsa; Weber, Samuel; Babacci, Benjamin; Arcani, Robin; Faucher, B.; Ménard, Amélie; Brodovitch, Alexandre; Mège, Jean Louis; Bardin, Nathalie

doi:10.1016/j.ijid.2021.09.079

Cited by 33 publications

(21 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is a growing amount of data suggesting that at least in a subset of patients there is an autoimmune component, with autoantibodies being produced against various epitopes [8,[40][41][42][43][44][45][46][47][48][49]. Specifically, chronic fatigue at least in a subset of patients has been associated with autoimmune mechanisms [8,[50][51][52]. For example, autoantibodies against neurotransmitter receptors (especially autoantibodies against β adrenergic and muscarinic cholinergic receptors), which are found in 30 % of patients with CFS are typically significantly elevated in Long/ Post-COVID patients [53].…”

Section: Epidemiology and Hypotheses Of Long/post-covid Pathogenesismentioning

confidence: 99%

COVID-19 and Therapeutic Apheresis

et al. 2022

View full text Add to dashboard Cite

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, is an unprecedented challenge for the global community. The pathogenesis of COVID-19, its complications and long term sequelae (so called Long/Post-COVID) include, in addition to the direct virus-induced tissues injury, multiple secondary processes, such as autoimmune response, impairment of microcirculation, and hyperinflammation. Similar pathological processes, but in the settings of neurological, cardiovascular, rheumatological, nephrological, and dermatological diseases can be successfully treated by powerful methods of Therapeutic Apheresis (TA). We describe here the rationale and the initial attempts of TA treatment in severe cases of acute COVID-19. We next review the evidence for the role of autoimmunity, microcirculatory changes and inflammation in pathogenesis of Long/Post COVID and the rationale for targeting those pathogenic processes by different methods of TA. Finally, we discuss the impact of COVID-19 pandemic on patients, who undergo regular TA treatments due to their underlying chronic conditions, with the specific focus on the patients with inherited lipid diseases being treated at the Dresden University Apheresis Center.

show abstract

Section: Epidemiology and Hypotheses Of Long/post-covid Pathogenesismentioning

confidence: 99%

COVID-19 and Therapeutic Apheresis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Some of the current hypotheses for the development of long COVID include SARS-CoV-2 tropism for the brainstem [ 68 •, 69 ], renin-angiotensin system dysfunction leading to central and peripheral circulatory abnormalities [ 70 ], chronic immune activation [ 71 , 72 ], mast cell activation [ 70 , 73 •], persistence of whole virus or remnants of SARS-CoV-2 [ 74 ], the ability of the virus to lead to hemostatic imbalance, reactivation of Epstein-Barr virus (EBV) [ 75 , 76 ] and other viruses, interference with fibrinolysis and promotion of micro-thrombi [ 77 , 78 ], and the development of auto-antibodies [ 79 – 81 ].…”

Section: Is Long Covid a Unique Illness Or Is Sars-cov-2 Another Trig...mentioning

confidence: 99%

Long-Term COVID 19 Sequelae in Adolescents: the Overlap with Orthostatic Intolerance and ME/CFS

et al. 2022

View full text Add to dashboard Cite

Purpose of Review To discuss emerging understandings of adolescent long COVID or post-COVID-19 conditions, including proposed clinical definitions, common symptoms, epidemiology, overlaps with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and orthostatic intolerance, and preliminary guidance on management. Recent Findings The recent World Health Organization clinical case definition of post-COVID-19 condition requires a history of probable or confirmed SARS-CoV-2 infection, with symptoms starting within 3 months of the onset of COVID-19. Symptoms must last for at least 2 months and cannot be explained by an alternative diagnosis. Common symptoms of the post-COVID-19 condition include, but are not limited to, fatigue, shortness of breath, and cognitive dysfunction. These symptoms generally have an impact on everyday functioning. The incidence of prolonged symptoms following SARS-CoV-2 infection has proven challenging to define, but it is now clear that those with relatively mild initial infections, without severe initial respiratory disease or end-organ injury, can still develop chronic impairments, with symptoms that overlap with conditions like ME/CFS (profound fatigue, unrefreshing sleep, post-exertional malaise, cognitive dysfunction, and orthostatic intolerance). Summary We do not yet have a clear understanding of the mechanisms by which individuals develop post-COVID-19 conditions. There may be several distinct types of long COVID that require different treatments. At this point, there is no single pharmacologic agent to effectively treat all symptoms. Because some presentations of post-COVID-19 conditions mimic disorders such as ME/CFS, treatment guidelines for this and related conditions can be helpful for managing post-COVID-19 symptoms. Supplementary Information The online version contains supplementary material available at 10.1007/s40124-022-00261-4.

show abstract

“…Targets of these auto‐Abs have been documented to include self‐Ag seen commonly in autoimmune conditions 342 , 343 , 344 , 345 and some have with molecular homology with SARS‐CoV‐2. 346 Some identified targets included phospholipids, 347 , 348 , 349 cytokines, 343 , 345 and type 1 interferons. 343 , 344 , 350 The disruption of these targeted self‐molecules could potentially explain procoagulant states, immune dysregulation, and the weakened antiviral responses, respectively, conditions commonly observed in COVID‐19.…”

Section: Autoreactive Features Of Asc After ...mentioning

confidence: 99%

COVID‐19 and plasma cells: Is there long‐lived protection?*

Nguyen

Lamothe

Woodruff

et al. 2022

Immunological Reviews

View full text Add to dashboard Cite

The SARS-CoV-2 pandemic arose in China at the end of 2019 and has caused over 450 million infections and more than 6 million deaths worldwide. Initially, the virus caused a wide range of clinical manifestations from asymptomatic and mild to severe and critical, leading to death in ~1.5% of infected individuals. Elderly patients were initially at risk of severe disease together with those who had co-morbid conditions, such as diabetes and obesity. Pneumonia and respiratory failure often led to hospitalization; however, this infection caused gastrointestinal and endothelial injury leading to systemic illness affecting multiple organ systems that included the brain and many others. 1 With mild illness even after recovery, post-acute sequelae of SARS-CoV-2 infection (PASC) has also been reported without clear underlying pathophysiologic mechanisms. 2 At first, sequelae were thought to occur only after severe infection, but now PASC has been commonly reported after

show abstract

Persistent IgG anticardiolipin autoantibodies are associated with post-COVID syndrome

Cited by 33 publications

References 10 publications

COVID-19 and Therapeutic Apheresis

COVID-19 and Therapeutic Apheresis

Long-Term COVID 19 Sequelae in Adolescents: the Overlap with Orthostatic Intolerance and ME/CFS

COVID‐19 and plasma cells: Is there long‐lived protection?*

Contact Info

Product

Resources

About